Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review

<p>Abstract</p> <p>Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after...

Full description

Bibliographic Details
Main Authors: Almaghrabi Mohammed, Supiot Stéphane, Paris Francois, Mahé Marc-André, Rio Emmanuel
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Radiation Oncology
Subjects:
Online Access:http://www.ro-journal.com/content/7/1/126
id doaj-eeaf78a1ccb64bffa88c3cf39a6361b9
record_format Article
spelling doaj-eeaf78a1ccb64bffa88c3cf39a6361b92020-11-24T21:01:37ZengBMCRadiation Oncology1748-717X2012-08-017112610.1186/1748-717X-7-126Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical reviewAlmaghrabi MohammedSupiot StéphaneParis FrancoisMahé Marc-AndréRio Emmanuel<p>Abstract</p> <p>Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing–related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node (LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases.</p> http://www.ro-journal.com/content/7/1/126CancerGastrointestinalLiverRadiotherapyRadiation biologySurgery
collection DOAJ
language English
format Article
sources DOAJ
author Almaghrabi Mohammed
Supiot Stéphane
Paris Francois
Mahé Marc-André
Rio Emmanuel
spellingShingle Almaghrabi Mohammed
Supiot Stéphane
Paris Francois
Mahé Marc-André
Rio Emmanuel
Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
Radiation Oncology
Cancer
Gastrointestinal
Liver
Radiotherapy
Radiation biology
Surgery
author_facet Almaghrabi Mohammed
Supiot Stéphane
Paris Francois
Mahé Marc-André
Rio Emmanuel
author_sort Almaghrabi Mohammed
title Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
title_short Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
title_full Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
title_fullStr Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
title_full_unstemmed Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
title_sort stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review
publisher BMC
series Radiation Oncology
issn 1748-717X
publishDate 2012-08-01
description <p>Abstract</p> <p>Advances in imaging and biological targeting have led to the development of stereotactic body radiation therapy (SBRT) as an alternative treatment of extracranial oligometastases. New radiobiological concepts, such as ceramide-induced endothelial apoptosis after hypofractionated high-dose SBRT, and the identification of patients with oligometastatic disease by microRNA expression may yet lead to further developments. Key factors in SBRT are delivery of a high dose per fraction, proper patient positioning, target localisation, and management of breathing–related motion. Our review addresses the radiation doses and schedules used to treat liver, abdominal lymph node (LN) and adrenal gland oligometastases and treatment outcomes. Reported local control (LC) rates for liver and abdominal LN oligometastases are high (median 2-year actuarial LC: 61 -100% for liver oligometastases; 4-year actuarial LC: 68% in a study of abdominal LN oligometastases). Early toxicity is low-to-moderate; late adverse effects are rare. SBRT of adrenal gland oligometastases shows promising results in the case of isolated lesions. In conclusion, properly conducted SBRT procedures are a safe and effective treatment option for abdominal oligometastases.</p>
topic Cancer
Gastrointestinal
Liver
Radiotherapy
Radiation biology
Surgery
url http://www.ro-journal.com/content/7/1/126
work_keys_str_mv AT almaghrabimohammed stereotacticbodyradiationtherapyforabdominaloligometastasesabiologicalandclinicalreview
AT supiotstephane stereotacticbodyradiationtherapyforabdominaloligometastasesabiologicalandclinicalreview
AT parisfrancois stereotacticbodyradiationtherapyforabdominaloligometastasesabiologicalandclinicalreview
AT mahemarcandre stereotacticbodyradiationtherapyforabdominaloligometastasesabiologicalandclinicalreview
AT rioemmanuel stereotacticbodyradiationtherapyforabdominaloligometastasesabiologicalandclinicalreview
_version_ 1716777520556146688